Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Merck announced results for Welireg in renal cell carcinoma after checkpoint inhibitor and anti-VEGF treatment • Source: Shutterstock

Merck & Co., Inc. stands to move the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) beyond its current indication of cancers associated with a rare genetic disorder, with results of a Phase III study showing it is effective in treating at least one of those cancers in a broader, heavily pretreated population as well.

Without disclosing data, the New Jersey-based drug maker announced results from the LITESPARK-005 trial comparing Welireg against everolimus in patients with advanced renal cell carcinoma (RCC) whose disease had progressed following treatment with a PD-1 or PD-L1 checkpoint inhibitor and a VEGF-targeting tyrosine kinase inhibitor

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By 

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.